The scopolamine market is estimated to augment at a CAGR of around 4.5% during the forecast period. Hyoscine is another name of the scopolamine which is majorly used to treat motion sickness & nausea and vomiting. Increasing the patient pool of the people suffering from stress and anxiety disorder due to motion sickness is the major factor for the market augmentation during the forecast period. Motion sickness is an uneasiness condition among people who travel.
Increase in the frequent traveling among people is directly proportional to the growth of the motion sickness drug market and so scopolamine market.
Significant growth in the developed, as well as developing countries, was witnessed in the aviation market, and once the COVID-19 pandemic effect diminishes, similar growth is expected in the aviation market. For instance, as per the US Department of Transportation, the US airlines carried around 5.0% more passengers on domestic flights and around 3.1% more passengers on international flights in 2018 as compared to 2017. Around 233.6 million passengers on international flights to and from the US was a record high, exceeding the previous high set in 2017. Air travel growth in Asia-Pacific is expected to remain to continue due to which a significant growth in the scopolamine market is expected in Asia-Pacific during the forecast period. Rising medical tourism in countries such as India, Indonesia, and Thailand is also a major factor contributing to the scopolamine market in the region.
A full report of Scopolamine Market is available at: https://www.omrglobal.com/industry-reports/scopolamine-market
Emerging countries such as China, India, Indonesia, and Vietnam are witnessing significant growth in the market. As per the World Bank, the total air passenger in during the period of 2014 and 2018 has witnessed a growth of 104% in Vietnam from 23 million in 2014 to 47 million in 2018. Similarly, India has witnessed a growth of around 100% as air passenger has increased from 82 million in 2014 to 164 million in 2018. Countries such as UK, Indonesia, UAE, and Saudi Arabia each have recorded an overall growth of more than 20% during the period of 2014-2018. Due to this, the demand for motion sickness drugs will be witnessed in the following countries.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/scopolamine-market
Scopolamine is available in all three forms that are oral, injection, and patches. However, patches are widely accepted for the treatment of nausea and vomiting due to motion sickness. Some of the major players offering scopolamine drugs include Novartis AG, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Baxter International Inc., Myungmoon Pharm Co. Ltd., Alchem International Pvt. Ltd., Caleb Pharmaceuticals, Inc., Phytex Australia, Fine Chemicals Corp., Perrigo Company plc and others.
Global Scopolamine Market- Segmentation
• Scopolamine Butyl bromide
• Scopolamine Base
By Dosage Type
For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/scopolamine-market
Global Scopolamine Market– Segment by Region
• United States
• United Kingdom
• Rest of Europe
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
• Alchem International Pvt. Ltd.
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• Cadila Healthcare Ltd.
• Caleb Pharmaceuticals, Inc.
• Fine Chemicals Corp.
• Guangzhou Hanfang Pharmaceutical Co., Ltd.
• Myungmoon Pharm Co. Ltd.
• Novartis AG
• Perrigo Co. plc
• Pfizer Inc.
• Phytex Australia
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit https://www.omrglobal.com
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404